TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO

Core Insights - TransCode Therapeutics, Inc. has completed its Phase 1a clinical trial for TTX-MC138, an investigational inhibitor of microRNA-10b, achieving its primary safety endpoint and establishing a recommended Phase 2 dose [1][5] Group 1: Clinical Trial Results - The primary objectives of the trial included safety, tolerability, pharmacokinetics, and establishing a Phase 2 dose, with 16 patients treated across four escalating dose levels [2] - No significant treatment-related safety events or dose-limiting toxicities were observed during the trial [2] - The median treatment duration was four months, with a range of two to twelve cycles, indicating good tolerability and disease control [3] - 44% of patients (7 out of 16) exhibited stable disease lasting four months or longer [3][8] Group 2: Efficacy and Future Plans - Preliminary data showed positive pharmacodynamic effects across all dose levels, consistent with preclinical models [3] - A patient with thyroid cancer showed a reversal in thyroglobulin levels during treatment, reaching undetectable levels [3] - The observed safety profile and durability of TTX-MC138's anti-tumor effects support advancing to a Phase 2a clinical trial [5][8] Group 3: About TTX-MC138 - TTX-MC138 is a first-in-class therapeutic candidate targeting microRNA-10b, which is critical in the progression of many metastatic cancers [6][7] - The drug has shown evidence of delivery to metastatic lesions and pharmacodynamic activity even at microdoses, suggesting a broad therapeutic window [6]